2019
DOI: 10.1177/1758835919851663
|View full text |Cite
|
Sign up to set email alerts
|

Management of metastatic cutaneous melanoma: updates in clinical practice

Abstract: In recent years, several drugs have been approved for the treatment of patients with metastatic cutaneous melanoma, completely reshaping the landscape of this aggressive disease. Immune therapy with cytotoxic T-lymphocyte antigen 4 and programmed cell death-1 inhibitors yielded significant and durable responses, achieving long-term disease control in up to 40% of the patients. BRAF inhibitors (BRAFi), in combination with MEK inhibitors, also resulted in improved overall survival compared with single-agent BRAF… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
30
0
6

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 34 publications
(36 citation statements)
references
References 106 publications
(133 reference statements)
0
30
0
6
Order By: Relevance
“…In the case of checkpoint inhibitors, the use of immunotherapy as a monotherapy is preferred in most patients due to its low toxicity. The combination of nivolumab and ipilimumab should be recommended especially in patients with asymptomatic CNS metastases [50][51][52]. However, the sequence of therapies, especially in patients with the present mutation in the BRAF gene, remains a problem.…”
Section: Strategy Of Management Of Patients With Advanced Melanomamentioning
confidence: 99%
See 1 more Smart Citation
“…In the case of checkpoint inhibitors, the use of immunotherapy as a monotherapy is preferred in most patients due to its low toxicity. The combination of nivolumab and ipilimumab should be recommended especially in patients with asymptomatic CNS metastases [50][51][52]. However, the sequence of therapies, especially in patients with the present mutation in the BRAF gene, remains a problem.…”
Section: Strategy Of Management Of Patients With Advanced Melanomamentioning
confidence: 99%
“…A very practical solution was proposed in the work by Schvartsman et al [50]. He distinguished two prognostic groups among patients with melanoma in inoperable grade III and in grade IV: low and high risk (table I).…”
Section: Combined Treatmentmentioning
confidence: 99%
“…In recent years, the treatment of metastatic melanoma includes chemotherapy, checkpoint inhibitors and so on. However, due to poor efficacy, the use of chemotherapy has declined dramatically over time . Checkpoint inhibitors is an immunotherapy that has revolutionized the treatment of metastatic melanoma.…”
Section: Introductionmentioning
confidence: 99%
“…However, due to poor efficacy, the use of chemotherapy has declined dramatically over time. 7,8 Checkpoint inhibitors is an immunotherapy that has revolutionized the treatment of metastatic melanoma. With the application of checkpoint inhibitors, there are also some unique adverse reactions called immunotherapy-related adverse reactions (irae).…”
Section: Introductionmentioning
confidence: 99%
“…many questions still remain to be answered: what is the best first-and second-line treatment or the best treatment sequence? New combinations of drugs, 'targeted therapies' combined with immunotherapies, immunotherapies combinations, and sequencing strategies are now underway in different clinical trials, highlighting the tendency towards a personalized medical approach [4][5][6][7][8][9].…”
mentioning
confidence: 99%